154 related articles for article (PubMed ID: 23220537)
1. Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening.
Jordheim LP; Marton Z; Rhimi M; Cros-Perrial E; Lionne C; Peyrottes S; Dumontet C; Aghajari N; Chaloin L
Biochem Pharmacol; 2013 Feb; 85(4):497-506. PubMed ID: 23220537
[TBL] [Abstract][Full Text] [Related]
2. The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor.
Cividini F; Pesi R; Chaloin L; Allegrini S; Camici M; Cros-Perrial E; Dumontet C; Jordheim LP; Tozzi MG
Biochem Pharmacol; 2015 Mar; 94(2):63-8. PubMed ID: 25656700
[TBL] [Abstract][Full Text] [Related]
3. Lead optimization and biological evaluation of fragment-based cN-II inhibitors.
Guillon R; Rahimova R; Preeti ; Egron D; Rouanet S; Dumontet C; Aghajari N; Jordheim LP; Chaloin L; Peyrottes S
Eur J Med Chem; 2019 Apr; 168():28-44. PubMed ID: 30798051
[TBL] [Abstract][Full Text] [Related]
4. Virtual screening identifies novel sulfonamide inhibitors of ecto-5'-nucleotidase.
Ripphausen P; Freundlieb M; Brunschweiger A; Zimmermann H; Müller CE; Bajorath J
J Med Chem; 2012 Jul; 55(14):6576-81. PubMed ID: 22731815
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of β-hydroxyphosphonate nucleoside analogues as cytosolic 5'-nucleotidase II potential inhibitors: synthesis, in vitro evaluation and molecular modeling studies.
Meurillon M; Marton Z; Hospital A; Jordheim LP; Béjaud J; Lionne C; Dumontet C; Périgaud C; Chaloin L; Peyrottes S
Eur J Med Chem; 2014 Apr; 77():18-37. PubMed ID: 24607586
[TBL] [Abstract][Full Text] [Related]
6. Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.
Iqbal J; Saeed A; Raza R; Matin A; Hameed A; Furtmann N; Lecka J; Sévigny J; Bajorath J
Eur J Med Chem; 2013; 70():685-91. PubMed ID: 24215819
[TBL] [Abstract][Full Text] [Related]
7. Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach.
Marton Z; Guillon R; Krimm I; Preeti ; Rahimova R; Egron D; Jordheim LP; Aghajari N; Dumontet C; Périgaud C; Lionne C; Peyrottes S; Chaloin L
J Med Chem; 2015 Dec; 58(24):9680-96. PubMed ID: 26599519
[TBL] [Abstract][Full Text] [Related]
8. Active and regulatory sites of cytosolic 5'-nucleotidase.
Pesi R; Allegrini S; Careddu MG; Filoni DN; Camici M; Tozzi MG
FEBS J; 2010 Dec; 277(23):4863-72. PubMed ID: 21029378
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic perspectives for cN-II in cancer.
Jordheim LP; Chaloin L
Curr Med Chem; 2013; 20(34):4292-303. PubMed ID: 23992314
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into the inhibition of cytosolic 5'-nucleotidase II (cN-II) by ribonucleoside 5'-monophosphate analogues.
Gallier F; Lallemand P; Meurillon M; Jordheim LP; Dumontet C; Périgaud C; Lionne C; Peyrottes S; Chaloin L
PLoS Comput Biol; 2011 Dec; 7(12):e1002295. PubMed ID: 22174667
[TBL] [Abstract][Full Text] [Related]
11. Initial studies to define the physiologic role of cN-II.
Filoni DN; Pesi R; Careddu MG; Camici M; Allegrini S; Collavoli A; Scarfone I; Zucchi F; Galli A; Tozzi MG
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1155-60. PubMed ID: 22132970
[TBL] [Abstract][Full Text] [Related]
12. Enforced expression of cytosolic 5'-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection.
Gray T; Morrey EL; Gangadharan B; Sumter TF; Spychala J; Archer DR; Spencer HT
Cancer Chemother Pharmacol; 2006 Jul; 58(1):117-28. PubMed ID: 16362297
[TBL] [Abstract][Full Text] [Related]
13. Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold.
Baqi Y; Lee SY; Iqbal J; Ripphausen P; Lehr A; Scheiff AB; Zimmermann H; Bajorath J; Müller CE
J Med Chem; 2010 Mar; 53(5):2076-86. PubMed ID: 20146483
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of molecular model-based discovery of ecto-5'-nucleotidase inhibitors on the basis of X-ray structures.
Furtmann N; Bajorath J
Bioorg Med Chem; 2013 Nov; 21(21):6616-22. PubMed ID: 24012379
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of cytosolic 5'-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells.
Careddu MG; Allegrini S; Pesi R; Camici M; Garcia-Gil M; Tozzi MG
Biochim Biophys Acta; 2008 Aug; 1783(8):1529-35. PubMed ID: 18445485
[TBL] [Abstract][Full Text] [Related]
16. Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.
Wang Y; Wang C; Zhu Y; Zhang Y; Chen B; Wu Y; Yao J; Miao Z
Bioorg Med Chem Lett; 2021 Feb; 34():127758. PubMed ID: 33359608
[TBL] [Abstract][Full Text] [Related]
17. Determination of the enzymatic activity of cytosolic 5'-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models.
Jordheim LP; Puy JY; Cros-Perrial E; Peyrottes S; Lefebvre I; Périgaud C; Dumontet C
Anal Bioanal Chem; 2015 Jul; 407(19):5747-58. PubMed ID: 25998135
[TBL] [Abstract][Full Text] [Related]
18. Virtual Screening Approach for the Identification of Hydroxamic Acids as Novel Human Ecto-5'-Nucleotidase Inhibitors.
Viviani LG; Piccirillo E; Ulrich H; Amaral AT
J Chem Inf Model; 2020 Feb; 60(2):621-630. PubMed ID: 31714079
[TBL] [Abstract][Full Text] [Related]
19. Stably transfected adherent cancer cell models with decreased expression of 5'-nucleotidase cN-II.
Bricard G; Cros-Perrial E; Machon C; Dumontet C; Jordheim LP
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):604-612. PubMed ID: 27906612
[TBL] [Abstract][Full Text] [Related]
20. A new, sensitive ecto-5'-nucleotidase assay for compound screening.
Freundlieb M; Zimmermann H; Müller CE
Anal Biochem; 2014 Feb; 446():53-8. PubMed ID: 24144488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
